Abstract
Abstract:Bartter syndrome is traditionally treated with large doses of oral potassium with or without suppression of the renin-angiotensin system. Since plasma renin activity is invariably elevated in Bartter syndrome, the availability of the direct renin inhibitor aliskiren should lead to the ability to maintain potassium levels without utilizing large doses of oral potassium. This case report is, to my knowledge, the first to show the efficacy of a renin receptor blocker in Bartter syndrome.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1. Rudin A. Bartter’s syndrome. A review of 28 patients followed for 10 years. Acta Med Scand 1988;224:165–171.RudinABartter’s syndrome. A review of 28 patients followed for 10 years.Acta Med Scand1988224165-1712. Sato M, Abe K, Yasujima M, et al. Bartter’s syndrome with normal urinary excretion of prostaglandin E: therapeutic effects of propranolol, spironolactone, indomethacin and potassium chloride. Tohoku J Exp Med 1980;131:151–159.SatoM]]AbeK]]YasujimaM&etal;Bartter’s syndrome with normal urinary excretion of prostaglandin E: therapeutic effects of propranolol, spironolactone, indomethacin and potassium chloride.Tohoku J Exp Med1980131151-1593. Cunningham RJ, Brouhard BH, Berger M, et al. Long-term use of propranolol, ibuprofen, and spironolactone in the management of Bartter’s syndrome. Pediatrics 1979;63:754–756.CunninghamRJ]]BrouhardBH]]BergerM&etal;Long-term use of propranolol, ibuprofen, and spironolactone in the management of Bartter’s syndrome.Pediatrics197963754-7564. Schwartz GJ, Cornfeld D. Bartter’s syndrome: clinical study of its treatment with salt loading and propranolol. Clin Nephrol 1975;4:45–51.SchwartzGJ]]CornfeldDBartter’s syndrome: clinical study of its treatment with salt loading and propranolol.Clin Nephrol1975445-515. Clementsen P, Høegholm A, Hansen CL, et al. Bartter’s syndrome—treatment with potassium, spironolactone and ACE-inhibitor. J Intern Med 1989;225:107–110.ClementsenP]]HøegholmA]]HansenCL&etal;Bartter’s syndrome—treatment with potassium, spironolactone and ACE-inhibitor.J Intern Med1989225107-1106. Jest P, Pedersen KE, Klitgaard NA, et al. Angiotensin-converting enzyme inhibition as a therapeutic principle in Bartter’s syndrome. Eur J Clin Pharmacol 1991;41:303–305.JestP]]PedersenKE]]KlitgaardNA&etal;Angiotensin-converting enzyme inhibition as a therapeutic principle in Bartter’s syndrome.Eur J Clin Pharmacol199141303-3057. van de Stolpe A, Verhoef GE, Hené RJ, et al. Total body potassium in Bartter’s syndrome before and during treatment with enalapril. Nephron 1987;45:122–125.van de StolpeA]]VerhoefGE]]HenéRJ&etal;Total body potassium in Bartter’s syndrome before and during treatment with enalapril.Nephron198745122-1258. Scherling B, Verder H, Nielsen MD, et al. Captopril treatment in Bartter’s syndrome. Scand J Urol Nephrol 1990;24:123–125.ScherlingB]]VerderH]]NielsenMD&etal;Captopril treatment in Bartter’s syndrome.Scand J Urol Nephrol199024123-1259. Aurell M, Rudin A. Effect of captopril on blood pressure, renal function, the electrolyte balance and the renin-angiotensin system in Bartter’s syndrome. Nephron 1983;33:274–278.AurellM]]RudinAEffect of captopril on blood pressure, renal function, the electrolyte balance and the renin-angiotensin system in Bartter’s syndrome.Nephron198333274-27810. Horký K, Schreiber V, Dvoráková J. The effect of long-term treatment with spironolactone on sodium pump abnormalities in the red blood cells of patients with Bartter’s syndrome. Exp Clin Endocrinol 1984;84:105–111.HorkýK]]SchreiberV]]DvorákováJThe effect of long-term treatment with spironolactone on sodium pump abnormalities in the red blood cells of patients with Bartter’s syndrome.Exp Clin Endocrinol198484105-11111. Nakada T, Shigematsu H, Bartter FC, et al. Nephropathologic characteristics of a woman with Bartter’s syndrome after prolonged treatment with spironolactone. Nephron 1980;26:78–84.NakadaT]]ShigematsuH]]BartterFC&etal;Nephropathologic characteristics of a woman with Bartter’s syndrome after prolonged treatment with spironolactone.Nephron19802678-8412. Jentsch TJ, Maritzen T, Zdebik AA. Chloride channel diseases resulting from impaired transepithelial transport or vesicular function. J Clin Invest 2005;115:2039–2046.JentschTJ]]MaritzenT]]ZdebikAAChloride channel diseases resulting from impaired transepithelial transport or vesicular function.J Clin Invest20051152039-204613. Okada M, Lertprasertsuke N, Tsutsumi Y. Quantitative estimation of renin-containing cells in the juxtaglomerular apparatus in Bartter’s and pseudo-Bartter’s syndromes. Pathol Int 2000;50:166–168.OkadaM]]LertprasertsukeN]]TsutsumiYQuantitative estimation of renin-containing cells in the juxtaglomerular apparatus in Bartter’s and pseudo-Bartter’s syndromes.Pathol Int200050166-168
